Psoriasis: TNF-α inhibitors and beyond

Kincaid, Lynne

doi:10.1016/s1359-6446(05)03507-5

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction2

Targeted Strategies For Manipulating the Mechanisms Of Disease1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2018

Publication Types

Select...

Article4

Other1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, injection site reactions were observed more frequently in the onercept group. In a phase III psoriasis trial of onercept, 2 patients developed sepsis, one of whom subsequently died (104). Two phase III clinical trials of onercept have been discontinued (105).…”

Section: Targeted Strategies For Manipulating the Mechanisms Of Diseasementioning

confidence: 99%

Psoriatic arthritis: Current concepts on pathogenesis‐oriented therapeutic options

Turkiewicz

Moreland

2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Section: Targeted Strategies For Manipulating the Mechanisms Of Diseasementioning

confidence: 99%

Psoriatic arthritis: Current concepts on pathogenesis‐oriented therapeutic options

Turkiewicz

Moreland

2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…This approach has recently been validated through the development of anti-chemokine monoclonal antibodies. [11][12][13][14] Chemokine function is regulated by numerous factors including dimerisation, binding to cell-surface glycosaminoglycans (GAGs), proteolytic processing and site-specific posttranslational modifications. We and others have characterised key recognition features of chemokines by their cognate receptors.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of polymers and nanoparticles bearing polystyrene sulfonate brushes for chemokine binding

et al. 2016

View full text Add to dashboard Cite

The movement of leukocytes to the site of inflammation in response to injury or infection is orchestrated by chemokines binding and signaling through cognate receptors. The interaction between sulfated tyrosine residues on the flexible N-terminal tail of the receptor with positively charged regions of the chemokine is one of the key recognition features that facilitates binding. In this manuscript we describe the synthesis of polymers and silica nanoparticles bearing polystyrene sulfonate brushes to mimic the sulfated tyrosine residues. We show that both the polymers and nanoparticles possess high binding affinity for the chemokine monocyte chemoattractant protein-1 (MCP-1) in monomeric and dimeric form. We also demonstrate key differences in the relative affinity for the chemokine for the free polymer versus the polymer-derived nanoparticle system.

show abstract

“…Pharm Dev Technol, Early Online:[1][2][3][4][5][6][7][8][9] Pharmaceutical Development and Technology Downloaded from informahealthcare.com by Nyu Medical Center on 06/11/15For personal use only.…”

mentioning

confidence: 99%

A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation

Avasatthi

Pawar

Dora

et al. 2015

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

show abstract

Psoriasis: TNF-α inhibitors and beyond

Cited by 5 publications

References 0 publications

Psoriatic arthritis: Current concepts on pathogenesis‐oriented therapeutic options

Psoriatic arthritis: Current concepts on pathogenesis‐oriented therapeutic options

Synthesis of polymers and nanoparticles bearing polystyrene sulfonate brushes for chemokine binding

A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation

Contact Info

Product

Resources

About